Spigel, DR, Ahn, MJ, Majem, M, Rodríguez, LM, Lee, KH, Carcereny, E, Hernández, AA, Insa, A, Cho, EK, Besse, B, Rha, SY, Weiss, J, D'Arcangelo, M, Im, SA, Kim, SW, Carneiro, BA, Gadgeel, SM, Mitchell, P, Asare, JM, Gainer, SD, Achour, I, Subramaniam, DS, Felip, E. Volrustomig plus platinum doublet chemotherapy (CTx) in first-line non-small cell lung cancer (NSCLC): Phase 1b trial update. Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).

Nguyen, D, Besse, B, Cho, BC, Lee, SH, Lee, KH, Lu, S, Cheng, Y, Yao, Y, Girard, N, Lin, CC, Felip, E, Aguilar, A, Charoentum, C, Cruz, FJSM, Majem, M, Lim, CS, Akamatsu, H, Hayashi, H, Yang, JCH, Kowalyszyn, R, Tiscoski, K, Franke, F, Ponomarenko, D, Arslan, C, Forster, M, Urban, D, Misch, D, Delmonte, A, Montes, LVG, Gadgeel, SM, Cruz-Correa, M, Peguero, J, Rousey, S, Gaffar, Y, Owen, S, Schuchard, J, Diels, J, Sermon, J, Sun, T, Ennis, M, Fennema, E, Daksh, M, Sethi, S, Bauml, JM, Campelo, MRG. Amivantamab Plus Lazertinib vs Osimertinib in First Line, EGFR-Mutant Advanced NSCLC: Patientrelevant Outcomes from MARIPOSA. Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).

Rodriguez-Vida, A, Valderrama, BP, Castellano, D, Pinto, A, Mellado, B, Puente, J, Climent, MA, Domenech, M, Vazquez, F, Perez-Gracia, JL, Bonfill, T, Morales-Barrera, R, Gonzalez-Billalabeitia, E, Garcia-del-Muro, X, Maroto, P, Navarro-Gorro, N, Juanpere, N, Juan, O, Bellmunt, J. Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study. ESMO Open. 2024; 9(9)DOI:10.1016/j.esmoop.2024.103690. PMID:39214051. IF:8.300(Q1/2D).

Tibau, A, Hwang, TJ, Avorn, J, Kesselheim, AS. Clinical value of guideline recommended molecular targets and genome targeted cancer therapies: cross sectional study. BMJ-British Medical Journal. 2024; 386DOI:10.1136/bmj-2023-079126. PMID:39164034. IF:42.700(Q1/1D).